Cargando…
XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial
BACKGROUND: Thin strut 3rd generation drug eluting stents offer the potential advantage over the previous generation of better technical performance and reduced neointimal proliferation parameters, which are linked to mid and late term device failure. AIM: To evaluate the performance of the Xlimus s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487315/ https://www.ncbi.nlm.nih.gov/pubmed/31061876 http://dx.doi.org/10.1016/j.ijcha.2019.100363 |
_version_ | 1783414477184565248 |
---|---|
author | Testa, Luca Pero, Gaetano Bollati, Mario Casenghi, Matteo Popolo Rubbio, Antonio Cuman, Magdalena Moreno, Raul Serra, Antoni Gomez, Joan Antoni Bedogni, Francesco |
author_facet | Testa, Luca Pero, Gaetano Bollati, Mario Casenghi, Matteo Popolo Rubbio, Antonio Cuman, Magdalena Moreno, Raul Serra, Antoni Gomez, Joan Antoni Bedogni, Francesco |
author_sort | Testa, Luca |
collection | PubMed |
description | BACKGROUND: Thin strut 3rd generation drug eluting stents offer the potential advantage over the previous generation of better technical performance and reduced neointimal proliferation parameters, which are linked to mid and late term device failure. AIM: To evaluate the performance of the Xlimus sirolimus-eluting stent (SES) against the Synergy everolimus-eluting stent (EES) in terms of device reendothelialization in patients undergoing PCI for coronary artery disease (CAD). METHODS: XLIMIT is a multicenter randomized controlled trial targeting 180 patients requiring percutaneous coronary interventions (PCI). Patients will be treated with Xlimus SES or Synergy EES implantation and randomization will be performed in a 2:1 ratio. The primary endpoint will be the reendothelialization grade of the Xlimus stent in terms of strut coverage and neointimal hyperplasia volume as compared to Synergy. Secondary endpoints will be represented by clinical and procedural outcomes. The first patient was enrolled on February 2019. CONCLUSIONS: A clearer understanding of the endothelialization process of new generation DES could significantly impact the treatment with dual antiplatelet therapy in the future. Moreover, although not powered for clinical end-points, the XLIMIT trial will provide randomized data in a population with minimal exclusion criteria. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03745053. Registered on November 19, 2018. |
format | Online Article Text |
id | pubmed-6487315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-64873152019-05-06 XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial Testa, Luca Pero, Gaetano Bollati, Mario Casenghi, Matteo Popolo Rubbio, Antonio Cuman, Magdalena Moreno, Raul Serra, Antoni Gomez, Joan Antoni Bedogni, Francesco Int J Cardiol Heart Vasc Original Paper BACKGROUND: Thin strut 3rd generation drug eluting stents offer the potential advantage over the previous generation of better technical performance and reduced neointimal proliferation parameters, which are linked to mid and late term device failure. AIM: To evaluate the performance of the Xlimus sirolimus-eluting stent (SES) against the Synergy everolimus-eluting stent (EES) in terms of device reendothelialization in patients undergoing PCI for coronary artery disease (CAD). METHODS: XLIMIT is a multicenter randomized controlled trial targeting 180 patients requiring percutaneous coronary interventions (PCI). Patients will be treated with Xlimus SES or Synergy EES implantation and randomization will be performed in a 2:1 ratio. The primary endpoint will be the reendothelialization grade of the Xlimus stent in terms of strut coverage and neointimal hyperplasia volume as compared to Synergy. Secondary endpoints will be represented by clinical and procedural outcomes. The first patient was enrolled on February 2019. CONCLUSIONS: A clearer understanding of the endothelialization process of new generation DES could significantly impact the treatment with dual antiplatelet therapy in the future. Moreover, although not powered for clinical end-points, the XLIMIT trial will provide randomized data in a population with minimal exclusion criteria. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03745053. Registered on November 19, 2018. Elsevier 2019-04-28 /pmc/articles/PMC6487315/ /pubmed/31061876 http://dx.doi.org/10.1016/j.ijcha.2019.100363 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Paper Testa, Luca Pero, Gaetano Bollati, Mario Casenghi, Matteo Popolo Rubbio, Antonio Cuman, Magdalena Moreno, Raul Serra, Antoni Gomez, Joan Antoni Bedogni, Francesco XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial |
title | XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial |
title_full | XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial |
title_fullStr | XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial |
title_full_unstemmed | XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial |
title_short | XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial |
title_sort | xlimus drug eluting stent: a randomized controlled trial to assess endothelialization. the xlimit trial |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487315/ https://www.ncbi.nlm.nih.gov/pubmed/31061876 http://dx.doi.org/10.1016/j.ijcha.2019.100363 |
work_keys_str_mv | AT testaluca xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT perogaetano xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT bollatimario xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT casenghimatteo xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT popolorubbioantonio xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT cumanmagdalena xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT morenoraul xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT serraantoni xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT gomezjoanantoni xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial AT bedognifrancesco xlimusdrugelutingstentarandomizedcontrolledtrialtoassessendothelializationthexlimittrial |